141 related articles for article (PubMed ID: 35262412)
1. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
[No Abstract] [Full Text] [Related]
2. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA; Riemann B; Hartmann MJM; Michel M; Faust M; Bruns CJ; Alakus H; Chiapponi C
Front Endocrinol (Lausanne); 2021; 12():748941. PubMed ID: 34630336
[TBL] [Abstract][Full Text] [Related]
5. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
[TBL] [Abstract][Full Text] [Related]
6. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
[TBL] [Abstract][Full Text] [Related]
7. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
8. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
Capdevila J; Awada A; Führer-Sakel D; Leboulleux S; Pauwels P
Cancer Treat Rev; 2022 May; 106():102380. PubMed ID: 35305441
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA Harboring the
Sato A; Tanabe M; Tsuboi Y; Niwa T; Shinozaki-Ushiku A; Seto Y; Murakami Y
Thyroid; 2021 Dec; 31(12):1822-1828. PubMed ID: 34541884
[No Abstract] [Full Text] [Related]
10. Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors.
Wu SS; Lamarre ED; Scharpf J; Prendes B; Ku JA; Silver N; Burkey B; Woody N; Campbell SR; Yilmaz E; Koyfman SA; Geiger J
Endocr Pract; 2023 Nov; 29(11):881-889. PubMed ID: 37597577
[TBL] [Abstract][Full Text] [Related]
11. The landscape of actionable genomic alterations in lung adenocarcinomas in India.
Sharma R; Kamireddy AP; Hussaini SM; Chatterjee S; Hasan Q; Jain J
Front Genet; 2023; 14():1256756. PubMed ID: 38155717
[TBL] [Abstract][Full Text] [Related]
12. Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.
R Teixeira M; Oliveira J; Borralho P; O Fernandes MG; Almodovar T; Fernandes I; Macedo D; Ferreira A; Barroso A; Teixeira E; Machado JC
Acta Med Port; 2022 Sep; 35(9):677-690. PubMed ID: 35816050
[TBL] [Abstract][Full Text] [Related]
13. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
Tarasova VD; Tsai J; Masannat J; Hernandez Prera JC; Hallanger Johnson J; Veloski C; Agosto Salgado S; McIver B; Drusbosky LM; Chung CH
Thyroid; 2024 Feb; 34(2):197-205. PubMed ID: 37962267
[No Abstract] [Full Text] [Related]
15. Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population.
Nindra U; Pal A; Lea V; Lim SH; Wilkinson K; Asghari R; Roberts TL; Becker TM; Farzin M; Rutland T; Lee M; MacKenzie S; Ng W; Wang B; Lee CS; Chua W
PLoS One; 2023; 18(10):e0292087. PubMed ID: 37796807
[TBL] [Abstract][Full Text] [Related]
16. Current perspectives on the management of patients with advanced
Elisei R; Grande E; Kreissl MC; Leboulleux S; Puri T; Fasnacht N; Capdevila J
Front Oncol; 2023; 13():1141314. PubMed ID: 37207147
[TBL] [Abstract][Full Text] [Related]
17. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer.
Nannini M; Repaci A; Nigro MC; Colapinto A; Vicennati V; Maloberti T; Gruppioni E; Altimari A; Solaroli E; Lodi Rizzini E; Monari F; De Leo A; Damiani S; Pagotto U; Pantaleo MA; de Biase D; Tallini G
ESMO Open; 2023 Dec; 8(6):102039. PubMed ID: 37879236
[TBL] [Abstract][Full Text] [Related]
19. Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care.
Sheffield BS; Beharry A; Diep J; Perdrizet K; Iafolla MAJ; Raskin W; Dudani S; Brett MA; Starova B; Olsen B; Cheema PK
Curr Oncol; 2022 Feb; 29(3):1326-1334. PubMed ID: 35323313
[No Abstract] [Full Text] [Related]
20. Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital.
Teuwen LA; Roets E; D'Hoore P; Pauwels P; Prenen H
Diagnostics (Basel); 2023 May; 13(9):. PubMed ID: 37175010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]